A case of small-cell esophageal cancer with chronic renal failure undergoing hemodialysis safely treated with cisplatin and etoposide by Murakami, Kentaro et al.
CASE REPORT
A case of small-cell esophageal cancer with chronic renal failure
undergoing hemodialysis safely treated with cisplatin
and etoposide
Kentaro Murakami • Yasunori Akutsu • Yukimasa Miyazawa •
Kiyohiko Shuto • Toru Shiratori • Masaya Uesato •
Isamu Hoshino • Taito Aoki • Hisahiro Matsubara
Received: 8 April 2011/Accepted: 29 June 2011/Published online: 18 July 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract A 54-year-old male undergoing hemodialysis
was admitted to our hospital because of difﬁculty in
swallowing. Esophagography and esophageal endoscopy
revealed an irregular ulcerated lesion in the cervical
esophagus. It was diagnosed as a small-cell esophageal
cancer from the biopsy sample. Computed tomography
showed a tumor inﬁltrating the trachea and a few lymph
node metastases in the cervix, upper mediastinum, and
abdomen. The patient was started on chemotherapy with
cisplatin (CDDP) and etoposide (VP-16), which had been
reported to be effective for small-cell lung cancer. The
patient was treated with CDDP (80 mg/m
2) on day 1 and
VP-16 (100 mg/m
2) on days 1, 3, and 5, every 4 weeks. On
the days of chemotherapy, hemodialysis was started as
soon as possible after completion of administration of the
agents. No severe side effects were observed. After 4
courses of therapy, the patient achieved a partial response.
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Introduction
Small-cell esophageal cancer (SCEC) is a rare tumor
accounting for approximately 1% of all esophageal
malignancies [1]. SCEC behaves aggressively with early
systemic metastasis, so prognosis is poor. Although com-
bined treatment including surgery, chemotherapy, and
radiotherapy has been attempted, no optimum treatment
approach for SCEC has been established. Recently, it has
been regarded as a systemic disease, and systemic che-
motherapy has become the treatment of choice. Because of
their histopathological similarity, the chemotherapy used
for small-cell lung cancer (SCLC) is often chosen for
SCEC.
Because pharmacokinetics in patients undergoing
hemodialysis differ from those in patients with normal
renal function, in hemodialysis patients it is difﬁcult to
determine a safe and effective dose and dosing schedule
for anticancer agents, including the optimum timing of
hemodialysis. Therefore an appropriate regimen of che-
motherapy for patients undergoing hemodialysis has not
been clearly established.
There are no reports in the literature of chemotherapy
for patients with SCEC maintained on hemodialysis. We
herein report a case with SCEC on hemodialysis to whom
cisplatin (CDDP) combined with etoposide (VP-16) was
administered safely and effectively.
Case report
Because of chronic glomerulonephritis a 54-year-old male
had been maintained on hemodialysis for approximately
10 years at his local hospital. He presented with difﬁculty in
swallowing and was examined by endoscopy in November
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DOI 10.1007/s10388-011-0284-62007, which led to diagnosis of esophageal cancer. Biopsy
specimens revealed the lesions to be SCEC (Fig. 1c). He
was admitted to our hospital in December, and esopha-
gography showed an elevated mass with ulceration, mea-
suring 7 cm in diameter,in the cervical esophagus (Fig. 1a).
Esophageal endoscopy revealed an irregularly elevated
lesion occupying approximately two-thirds of the circum-
ference, with ulceration, 18–23 cm from his incisors
(Fig. 1b). Computed tomography (CT) revealed a solid
mass, measuring 28 mm in a diameter, in the cervical
esophagus, which invaded the trachea, and lymph node
enlargement in the cervical paraesophageal area, the
supraclavicular area, the tracheobronchial area, and the area
along the lesser curvature (Fig. 1d). Blood chemistry
analysis revealed an elevated serum level (107.9 pg/ml) of
pro-gastrin-releasing peptide (Pro-GRP).
The lesion was diagnosed as T4, N1, M1, and stage IV
(UICC TNM classiﬁcation). Because the tumor was judged
to be unresectable, chemotherapy was selected as the
treatment for this case. We knew CDDP and VP-16 were
effective in the treatment of SCLC, leading us to a decision
to use these anticancer agents for the systemic chemo-
therapy. The chemotherapeutic regimen consisted of
CDDP on day 1 and VP-16 on days 1, 3 and 5, every
4 weeks. In the conventional schedule of CDDP and VP-16
therapy for SCLC, VP-16 is administered on days 1–3.
However, we wanted to match the day of administration
with the day of dialysis without reducing the total dosage
of VP-16. Therefore, we chose a different schedule of
VP-16, and administered it on days 1, 3, and 5. The
administration schedule for the two agents on day 1 con-
sisted of intravenous injection of VP-16 in 500 ml normal
saline for 120 min and of CDDP for 60 min after the end of
VP-16 infusion, and no hydration was performed. For this
patient, standard-dose chemotherapy was administered,
consisting of CDDP and VP-16 at 80 and 100 mg/m
2,
respectively. He was hemodialyzed with a cellulose triac-
etate dialyzer three times per week, for approximately 4 h
per hemodialysis session. On the days of chemotherapy,
hemodialysis was started as soon as possible (within
30 min) after completion of administration of the chemo-
therapeutic agents (Fig. 2)[ 2].
Effects of chemotherapy
After the fourth course was ﬁnished, the lesion was eval-
uated. A partial response was noted, and the patient was
able to eat solid food after the treatment. Esophagography
showed that the tumor was reduced to 4 cm and had
become ﬂatter (Fig. 3a). Esophageal endoscopy revealed
that the tumor which projected into the lumen had almost
disappeared. Only a mildly irregular mucosa and a minute
elevated mass remained in the cervical esophagus,
22–24 cm from his incisors (Fig. 3b). A CT scan showed a
solid mass which had decreased to 21 mm in size, in the
cervical esophagus, which did not seem to invade the tra-
chea. The size of the lymph node swelling had also
decreased (Fig. 3c). The serum level of Pro-GRP fell after
Fig. 1 a Esophagography
revealed an elevated mass with
ulceration, measuring 7 cm in
diameter, in the cervical
esophagus. b Esophageal
endoscopy revealed an
irregularly elevated lesion
occupying approximately two-
thirds of the circumference,
with ulceration, 18–23 cm from
his incisors. c Histopathologic
examination of the biopsy
specimens revealed that the
tumor was composed of small,
round-to-oval cells with
hyperchromatic nuclei and scant
cytoplasm (H&E stain 9100).
d Computed tomography (CT)
revealed a solid mass,
measuring 28 mm in a diameter,
in the cervical esophagus, which
invaded the trachea
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123the course of chemotherapy and rose after the interval
between chemotherapy. The minimum value of pro-GRP
was 38.5 pg/ml, but after 4 courses of this regimen, the
serum level of Pro-GRP was 165.7 pg/ml. An additional 5
courses of treatment were administered. At that time,
examinations had shown no progressive growth of the
tumor. However, 12 months after the initial treatment
disease progression was observed. The CT scans showed
regrowth of the main tumor and multiple cervical lymph
node metastases. Because the patient’s pain had worsened
because of enlargement of the lymph node metastases, and
his performance status had abruptly worsened, palliative
radiation (30 Gy) was administered for the purpose of pain
relief. However, because the patient could not eat and was
markedly emaciated, we judged that the continuation of the
treatment would be difﬁcult, so best supportive care was
provided. One month after stopping treatment, his body
weight continued to decrease, and marked general edema
occurred. The patient died as a result of disease
progression.
Toxicity
With regard to the toxicity of this chemotherapy regimen,
the patient complained of only mild nausea and loss
of appetite (Grade 1 by NCI-CTCAE v4.0). Although
occasional afebrile neutrocytopenia (Grade 3) was apparent
from the blood chemistry data, we were easily able to treat
it with granulocyte colony stimulating factor (G-CSF). The
patient had nephrogenic anemia (hemoglobin 7.2 g/dl,
packed cell volume 23.0%) just before chemotherapy, and
so experienced exacerbation of his anemia (Grade 4) as a
result of the chemotherapy. Therefore, a blood transfusion
was performed twice during the course of treatment. These
complications were tolerable.
Pharmacokinetics
We measured plasma levels of total CDDP (t-CDDP) and
VP-16. Venous blood samples were collected into tubes
just before and after drug administration, then 0.5, 1, 2, 3,
4, 5, 12 h, 1 (24 h), 2, 3, 4 days, and 1, 2, 3 weeks after
administration. After separating plasma from each sample,
the concentrations of t-CDDP and VP-16 were measured in
a portion of the plasma. As shown in Figs. 4 and 5,w e
compared the time–concentration curves of t-CDDP and
VP-16 between the patient with renal insufﬁciency and
those with normal renal function. Figures 4b and 5b were
provided by Dr Masumi Sawada and Dr Akira Wakui,
respectively. The pharmacokinetic parameters, including
half-life (t1/2) and area under the curve (AUC), were cal-
culated for CDDP and VP-16.
The t-CDDP concentration decreased abruptly immedi-
ately after administration of CDDP (aphase); afterward it
decreased more slowly (bphase) (Fig. 4a). This biphasic
pattern of the pharmacokinetics was similar to that for
patients with normal renal function (in a phase 1 clinical
trial) [3] (Fig. 4b). The t-CDDP concentration on initiation
of hemodialysis was 2.31 lg/ml. The maximum drug
concentration (Cmax) (CDDP 50 mg/body) as shown in
Fig. 4b was higher than that observed in our data (CDDP
120 mg/body). However, in other studies, it was reported tha
the Cmax was 1.40, 0.98, 1.07 lg/ml (CDDP 80 mg/body)
[4], 3.31 lg/ml (CDDP 80 mg/m
2)[ 5], and 2.90 lg/ml
(CDDP 100 mg/m
2)[ 6]. The reason why the value of Cmax
in a phase 1 clinical trial tends to be high is unclear.
However, our data were consistent with those in previous
reports. It decreased to 1.39 lg/ml at 0.5 h, and was
1.56 lg/ml 4 h after the initiation. Most t-CDDP was
removed in the ﬁrst 30 min of dialysis. The lower limit of
detection of t-CDDP was 0.1 lg/ml. The maximum
t-CDDP concentration was 2.31 lg/ml, and it had
decreased to 0.17 lg/ml 28 days after the administration of
CDDP. CDDP remained in the plasma for at least 28 days,
but the last concentration approached the lower limit of
detection. We also measured the plasma levels of t-CDDP
in the ﬁrst and second courses and compared each point in
both courses. The t-CDDP concentrations in the second
course were signiﬁcantly higher than those in the ﬁrst
Fig. 2 The chemotherapeutic regimen consisted of CDDP on day 1
and VP-16 on days 1, 3, and 5, every 4 weeks. The schedule of
administration of the two agents on day 1 consisted of intravenous
injection of VP-16 for 120 min then CDDP for 60 min after the end
of VP-16 infusion. This patient was hemodialyzed three times per
week, for approximately 4 h per hemodialysis session. On the days of
chemotherapy, hemodialysis was started as soon as possible (within
30 min) after completion of administration of the agents
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123course (Wilcoxon t test, P\0.01), indicating a cumulative
effect of CDDP in this regimen. The t1/2a was 0.036 h, and
t1/2b was 119 h for the ﬁrst course of CDDP. In contrast,
the t1/2a was 0.411 h and t1/2b was 164 h for the second
course. The AUC was 265 and 363 lg h/ml in the ﬁrst and
second courses, respectively. The t1/2 was extended and the
AUC was increased in the second course in comparison
with the ﬁrst course. Many reports have described that the
t1/2b was approximately 100 h in patients with normal renal
function [6], and Tokunaga et al. [4] reported that the t1/2a
for CDDP was 0.53 ± 0.07 h, t1/2b was 94.2 ± 11.6 h, and
AUC was 71.3 ± 6.26 lg h/ml after administration of
90.8 ± 6.34 mg to patients with normal renal function. In
this case, we obtained a similar t1/2 value, but the AUC
tended to be greater than for patients with normal renal
function.
The VP-16 maximum concentrations were 9.96, 10.44,
and 10.45 lg/ml after the three administrations and rapidly
decreased to 5.06, 6.07, and 5.76 lg/ml 4 h after adminis-
tration (aphase). The concentrations then decreased gradu-
ally(bphase)(Fig. 5a).Thepharmacokineticshadabiphasic
pattern which was also comparable with the curves for
patients with normal renal function (in a phase 1 clinical
trial) [7] (Fig. 5b). The concentration had decreased to
1.45 lg/ml at 24 h and 0.62 lg/ml at 48 h after adminis-
tration, which was approaching the lower limit of detection.
Almost all of the VP-16 in the plasma was excreted within
48 h. Comparison of each point after the ﬁrst and second
administrations revealed the VP-16 concentrations were not
signiﬁcantly different (Wilcoxon t test, P = 0.068), and no
signiﬁcant cumulative effect caused by the alternate-day
administration for 3 days was apparent. We also evaluated
thepharmacokineticparametersofVP-16inthispatient.The
t1/2a was 2.31 h and t1/2b was 17.2 h after the ﬁrst adminis-
tration in the ﬁrst course of treatment, and the t1/2a was
3.10 h and t1/2b was 16.9 h after the second administration
during the ﬁrst course. The AUC values were 128 and
139 lg h/ml, respectively, after the ﬁrst and second
administrations during the ﬁrst course. There was little dif-
ference between t1/2 and AUC after the ﬁrst and second
administrations. On the other hand, Wakui et al.[7] reported
that the t1/2a was 0.13 and 0.30 h, t1/2b was 4.85 and 4.01 h,
and the AUC was 95.7 and 94.8 lg h/ml, respectively, after
the administration of 120 mg/m
2 in patients with normal
renal function (based on a phase 1 clinical trial). This sug-
gested that there was a tendency for both the t1/2 and AUC to
increase in this dialysis patient in comparison with patients
with normal renal function.
Fig. 3 a Esophagography
showed the tumor was reduced
to 4 cm and had become ﬂatter.
b Esophageal endoscopy
revealed that the tumor that
projected into the lumen had
almost disappeared. Only a
mildly irregular mucosa and a
minute elevated mass remained
in the cervical esophagus,
22–24 cm from his incisors. c A
CT scan showed a solid mass
which had decreased to 21 mm
in size, in the cervical
esophagus, which did not seem
to invade the trachea. The size
of lymph node swelling had also
decreased
212 Esophagus (2011) 8:209–215
123Discussion
SCEC is a rare tumor accounting for approximately 1% of
all esophageal malignancies [1]. There is no established
treatment for the disease, but combination chemotherapy
consisting of CDDP and VP-16, such as is given for SCLC,
is generally administered.
It is well known that patients with chronic renal failure
suffer from malignancies at high frequency, as reported by
Matas et al. [8]. With the increase in the number of dialysis
patients, cases in which malignancies are detected during a
dialysis period have increased.
When an anticancer agent is administered to a patient
with chronic renal failure, it is necessary to consider the
metabolic pathway of the anticancer agent and to adjust the
administration method in order to reduce side effects while
maintaining antitumor efﬁcacy. CDDP is a chemothera-
peutic agent that is excreted into urine. Its half-life (t1/2)
isapproximately 100 h, which is longer than that of other
anticancer agents, so we were concerned about accumulation
of the drug in the patient with chronic renal failure. Some
papers have indicated that the dose should be reduced to
50% in patients with renal insufﬁciency [9, 10]. The major
route of excretion of VP-16 is the bile and stool. Urinary
excretion by patients with normal renal function is 30–40%
after intravenous administration. The dose that should
be given to patients with chronic renal failure is contro-
versial, and some papers have reported a need to reduce the
dose [9, 10]. However, it is controversial whether antitumor
activity is retained after dose reduction. There have been of
reports on CDDP and VP-16 chemotherapy for a dialysis
patients with SCEC.
In this case, we ﬁrst discussed the safety of this regimen.
The patient complained of mild nausea and appetite loss,
but his dietary intake was reduced by half for approxi-
mately 3 days only after administration of CDDP.
Although frequent anemia and neutrocytopenia were
observed, the toxicity was tolerable. The nadir was shown
to be 16–23 days after administration, and did not last
longer than in patients with normal renal function. We
Fig. 4 The t-CDDP concentration decreased abruptly immediately
after administration of CDDP (aphase) and then decreased slowly
(bphase). This biphasic pattern of the pharmacokinetics was similar
to that for patients with normal renal function. a The hemodialysis
patient. b Patients with normal renal function (the ﬁgure was provided
by Dr Masumi Sawada, Osaka University). c Pharmacokinetic param-
eters for CDDP
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123suggest that this regimen can be safely administered even
to dialysis patients.
We also studied the efﬁcacy of the regimen in this case.
SCEC is classiﬁed as limited disease (LD) or extensive
disease (ED) according to the Veterans Administration
Lung Group staging system [11]. It has been reported that
the median survival time (MST) for ED is 7.0 months, and
that 1-year survival is 29.3% [12]. In our case the patient
was staged as ED, and he maintained stable disease (SD)
for 12 months, and survived for 13 months. In comparison
with the previous report, the curative effect in this case was
slightly better. Our ﬁndings therefore suggest that this
regimen is effective for treatment of dialysis patients.
We also studied the good results in terms of safety and
efﬁcacy and their relationship to the pharmacokinetics. The
timing of hemodialysis initiation after administration of the
anticancer agent and the doses of the anticancer agents
were very important in terms of the safety and efﬁcacy of
the treatment.
In terms of safety, it is necessary to prevent serious side
effects associated with CDDP accumulation. The free-
CDDP (f-CDDP) could be removed easily by hemodialysis.
However, protein binding of CDDP in the plasma is
approximately 90%, and f-CDDP binds to plasma proteins
immediately and strongly [13]. Protein-bound CDDP is
difﬁcult to remove effectively. In this case, the f-CDDP
was removed quickly by hemodialysis immediately after its
administration, thus blocking some of the binding to the
plasma proteins. As a result, the t-CDDP concentration–
time curve and the value of t1/2 in this case were almost
equal to those for patients with normal renal function
reported previously. On the basis of a literature review, the
AUC for CDDP was higher than for patients with normal
renal function. It is said that the AUC of CDDP correlates
with its side effects. However, there are individual differ-
ences in clinical side effects. In this case, there were no
severe side effects. However, it should be kept in mind that
there is a risk of severe side effects, especially for patients
Fig. 5 The VP-16 concentration decreased rapidly during the ﬁrst 4 h
after administration (aphase) and then decreased gradually (bphase).
The biphasic pattern of the pharmacokinetics was comparable with
that for patients with normal renal function. a The hemodialysis
patient. b Patients with normal renal function (the ﬁgure was provided
by Dr Akira Wakui, Tohoku University). c Pharmacokinetics param-
eters for VP-16
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123with compromised renal function. Approximately 4 weeks
were required for CDDP to be excreted completely. The
dosing interval in this regimen was 4 weeks, but the
cumulative effect of CDDP was clear upon comparison of
the pharmacokinetics in the ﬁrst and second courses. In this
case, there was no clinically signiﬁcant increase in the side
effects during the second course, but it is necessary to take
care when administering this regimen on this schedule. It
has been reported that the efﬁcacy of platinum-containing
drugs depends on both the length of exposure and the
concentration, and the anti-tumor effect was likely to cor-
relate with the AUC, because it contains both elements.
When CDDP is administered to a dialysis patient, the AUC
depends not only on the dose of drug administered but also
on the timing of dialysis initiation. In this case, the AUCs
were increased compared with patients with normal renal
function. This may be one of the reasons we obtained a
slightly better anti-tumor effect.
We also analyzed the pharmacokinetics of VP-16, which
is excreted mainly through the bile and stool, only slightly
in the urine, unlike CDDP. Because a small percentage of
the administered VP-16 is excreted into the urine, the dose
of the anticancer agent and the dialysis schedule may not
affect the pharmacokinetics signiﬁcantly. However, some
papers recommended dose reduction of VP-16 for dialysis
patients, because of its poor dialyzability. In this case, the
maximum concentration was almost equal to that in
patients with normal renal function, but the t1/2 was longer.
A tendency for VP-16 to accumulate in the hemodialysis
patients was noted. However, a large quantity was excreted
in\48 h, and it was revealed that there was no cumulative
effect by comparison of the pharmacokinetics after each
administration. In terms of safety, the usual dose could be
safely administered by starting hemodialysis soon after
administration of the drug. In terms of efﬁcacy, the AUC
was larger than that for patients with a normal renal
function, and thus there is a possibility that we obtained a
slightly better anti-tumor effect compared to patients with
normal renal function.
Chemotherapy using this regimen was performed safely
without severe side effects, and almost equal anti-tumor
efﬁcacy was observed compared with patients with normal
renal function. On the basis of the above-mentioned
pharmacokinetics, it was suggested that the good results
were because of the time–concentration relationship, which
resembled that for patients with normal renal function. In
terms of safety and efﬁcacy, this regimen, which consisted
of the usual dose of chemotherapeutic agents, and the
initiation of dialysis immediately after administration of
the agents, was considered to be reasonable.
In conclusion, this full-dose combination chemotherapy
regimen comprising CDDP and VP-16 seems to be safe and
effective against esophageal SCEC in patients undergoing
regular hemodialysis. Further study is needed for selection
of suitable chemotherapeutic regimens, the optimum dose
of each drug, and the timing of hemodialysis.
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